Adjuvant chemotherapy as a component of complex treatment for skin melanoma

Voprosy Onkologii

Volumn 54, Issue 2, 2008, Pages 170-177

  Koudryavtsev, D V ^a   Koudryavtseva, G T ^a   Mardynsky, Yu S ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPHADENECTOMY; MALE; MELANOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 45149111618     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Al-Dewachi H.S., Wright N.A., Appleton D.R., Watson A. J. Cell population kinetics in the mouse jejunal crypt // Virchows Arch. B Cell Pathol. - 1975. - Vol. 18. - P. 225-242.
6. Arancia G., Molinari A., Calcabrini A. et al. Intracellular P-glycoprotein in multidrug resistant tumor cells // Ital. J. Anat. Embryol. - 2001. - Vol. 106 (Suppl. 1). - P. 59-68.
7. Balch C.M., Murray D., Presant C., Bartolucci A.A. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma // Surgery. - 1984. - Vol. 95. - P. 454-459.
8. Bassukas I.D., Arai A., Schell H., Hornstein O.P. Growth and cell kinetics of human hair papilla cells in vitro. An autoradiographic and flow cytometric study // Cell Prolif. - 1991. - Vol. 24. - P. 367-74.
9. Berger W., Elbling L., Minai-Pour M. et al. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines // Int. J. Cancer. - 1994. - Vol. 59. - P. 717-723.
10. De Marco F., Foppoli C., Coccia R. et al. Ectopic deposition of melanin pigments as detoxifying mechanism: a paradigm for basal nuclei pigmentation // Biochem. Biophys. Res. Commun. - 2004. - Vol. 314. - P. 631-637.
11. Desai P.B., Duan J., Sridhar R., Damle B.D. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole // Methods Find Exp. Clin. Pharmacol. - 1997. - Vol. 19. - P. 231-239.
12. Hakansson A., Gustafsson B., Abdiu A. et al. Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy // Cancer Immunol. Immunother. - 2003. - Vol. 52. - P. 249-254.
13. Hancock B.W., Wheatley K., Harris S. et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma // J. Clin. Oncol. - 2004. - Vol. 22. - Vol. 53-61.
14. Heere-Ress E., Thallinger C., Lucas T. et al. Bcl-X (L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy // Int. J. Cancer. - 2002. - Vol. 99. - P. 29-34.
15. Hennessy A., Oh C., Diffey B. et al. Eumelanin and pheomelanin concentrations in human epidermis before and after UVB irradiation // Pigment. Cell Res. - 2005. - Vol. 18. - P. 220-223.
16. Kim E.M., SivanandhAmer. M., Stavropoulos C.I. et al. Overview analysis of adjuvant therapies for melanoma-a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials // Surg. Oncol. - 2001. - Vol. 10. - P. 53-59.
17. Kirkwood J.M., Manola J., Ibrahim J. at al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma // Clin. Cancer Res. - 2004. - Vol. 10. - P. 1670-1677.
18. Kleeberg U.R., Suciu S., Brocker E.B. et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis // Europ. J. Cancer. - 2004. - Vol. 40. - P. 390-402.
19. Kretschmer L., Helmbold P., Emmert S., Marsch W.C. Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma // Hautarzt. - 2002. - Vol. 53. - No 8. - P. 536-541.
20. Liedert B., Materna V., Schadendorf D. et al. Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2 -Arrest in Melanoma Cells Resistant to Cisplatin // J. Invest. Dermatol. - 2003. - Vol. 121. - Vol. 172-176.
21. Ma S., Egyhazi S., Martenhed G. et al. Analysis of O (6)-methylguanine- DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy // Melanoma Res. - 2002. - Vol. 12. - P. 335-342.
22. Molinari A., Calcabrini A., Meschini S. et al. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells // Int. J. Cancer. - 1998. - Vol. 75. - P. 885-893.
23. Molinari A., Toccacieli L., Calcabrini A. et al. Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells // Anticancer Res. - 2000. - Vol. 20. - P. 2691-2696.
24. Newburger A.E., Weinstein G. Cell proliferation patterns in human malignant melanoma, in vivo // Cancer (Philad.). - 1980. - Vol. 46. - P. 308-313.
25. Pagani E., Falcinelli S., Pepponi R. et al. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and 06-methylguanine-DNA methyltransferase activity // Int. J. Oncol. - 2007. - Vol. 30. - P. 443-451.
26. Pak B.J., Chu W., Lu S.J. et al. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2 // Cancer Metastasis Rev. - 2001. - Vol. 20. - P. 27-32.
27. Passagne I., Evrard A., Depeille P. et al. O (6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C // Toxicol. Appl. Pharmacol. - 2006. - Vol. 211. - P. 97-105.
28. Pectasides D., Alevizakos N., Bafaloukos D. et al. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma // Amer. J. Clin. Oncol. - 1994. - Vol. 17. - P. 55-59.
29. Pepponi R., Marra G., Fuggetta M.P. et al. The effect of 06-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis (2-chloroethyl)1-nitrosourea, and cisplatin // J. Pharmacol. Exp. Ther. - 2003. - Vol. 304. - P. 661-668.
30. Punt C.J., Eggermont A.M. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies // Ann. Oncol. - 2001. - Vol. 12. - P. 1663-1666.
31. Sabel M.S., Sondak VK. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? // Drugs. - 2003. - Vol. 63. - P. 1053-1058.
32. Schadendorf D., Makki A., Stahr C. et al. Membrane transport proteins associated with drug resistance expressed in human melanoma // Amer. J. Pathol. - 1995. - Vol. 147. - P. 1545-1552.
33. Soengas M.S., Capodieci P., Polsky D. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma // Nature. - 2001. - Vol. 409. - No 6817. - P. 207-211.
34. Stables G.I., Doherty VR., MacKie R.M. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma // Brit. J. Dermatol. - 1992. - Vol. 127. - P 505-508.
35. Tang L., Tron V.A., Reed J.C. et al. Expression of apoptosis regulators in cutaneous malignant melanoma // Clin. Cancer Res. - 1998. - Vol. 4. - P. 1865-1871.
36. Verma S., Quirt I., McCready D. et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma // Cancer (Philad.). - 2006. - Vol. 106. - P. 1431-1442.
37. Vlaykova T., Talve L., Hahka-Kemppinen M. et al. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response // Oncology. - 2002. - Vol. 62. - P. 259-268.
38. Weinstein G.D., Mooney K.M. Cell proliferation kinetics in the human hair root // J. Invest. Dermatol. - 1980. - Vol. 74. - P. 43-46.
39. Wolf M., Bauder-Wust U., Haberkorn U. et al. Alkylating benzamides with melanoma cytotoxicity, role of melanin, tyrosinase, intracellular pH and DNA interaction // Melanoma Res. - 2005. - Vol. 15. - P. 383-391.
40. Wright N.A., Al-Dewachi H.S., Appleton D.R., Watson A.J. Cell population kinetics in the rat jejunal crypt // Cell Tissue Kinet. - 1975. - Vol. 8. - P. 361-368.